Clinical trial
Efficacy, Safety, Preference and Response Duration of Clobex® Spray and…
NCT00437255 · Galderma R&D, Industry · Completed
Key facts
| NCT number | NCT00437255 |
|---|---|
| Title | Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis |
| Official title | An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis |
| Lead sponsor | Galderma R&D, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Plaque Psoriasis |
| Intervention type | Drug |
| Interventions | Clobetasol Propionate, 0.05%, Calcipotriene and betamethasone dipropionate ointment |
| Enrollment | 122 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Feb 19, 2007 |
| Last update posted | Jul 29, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: